<DOC>
	<DOCNO>NCT01363336</DOCNO>
	<brief_summary>This study post-marketing surveillance Japan , local prospective , company sponsor observational study patient treat Adalat CR hypertension diabetes and/or chronic kidney disease . The objective study ass safety efficacy profile use Adalat CR real clinical practice . A total 2,000 patient recruit observed 6 month . Then , patient microalbumin urea serum creatinine continuously monitor additionally follow 6 month .</brief_summary>
	<brief_title>Post-marketing Surveillance Hypertensive Patients With Diabetes and/or Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Patient administer Adalat CR hypertension diabetes and/or chronic kidney disease ( CKD ) CKD stage 5 CDK dialysis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Adalat</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Chronic kidney disease</keyword>
</DOC>